gle

Sirpiglenastat (DRP-104), a glutamine antagonist and prodrug of DON, exhibits antitumor activity by inhibiting glutamine metabolism and stimulating both the innate and adaptive immune systems.

Oglemilast (GRC 3886) suppresses pulmonary cell infiltration, including eosinophilia and neutrophilia in vitro and in vivo. Oglemilast is an effective and orally active phosphodiesterase-4 (PDE4) inhibitor (IC50: 0.5 nM for PDE4D3). Oglemilast has the potential for inflammatory airway diseases.

Glecirasib (JAB-21822) is an orally active KRAS G12C inhibitor that selectively binds to and inhibits the activity of KRAS G12C mutants, thereby inhibiting KRAS G12C-dependent signaling. In animal models, KRAS G12C inhibitor 36 showed a favorable safety profile and potential to inhibit tumor growth.

Glecaprevir (ABT-493) is an HCV NS3 4A protease inhibitor, (IC50s: 3.5-11.3 nM).

Telaglenastat (CB 839) (IC50 of 24 nM), an effective, specific, and oral inhibitor, which is bioavailable glutaminase, for recombinant human GAC.

Englerin A, a TRPC4 and TRPC5 channel agonist, is a compound from the East African plant Phyllanthus engleri with analgesic, anti-inflammatory, and anticancer activities that induces necrosis in human renal cancer cells.

BigLEN (mouse) acetate is a potent and selective agonist of orphan G protein-coupled receptor 171 (GPR171), with a Kd of ∼0.5 nM.

Glesatinib is an orally active and potent dual inhibitor of MET SMO. Glesatinib is also a tyrosine kinase inhibitor. It antagonizes P-glycoprotein mediated multidrug resistance (MDR) in NSCLC.

BigLEN(rat) is a potent GPR171 agonist with an EC50 of 1.6 nM [1].

Kanglexin is an orally active novel anthraquinone compound. It inhibits NLRP3 inflammasome activation and pyroptosis, offering cardioprotective benefits. By stimulating the FGFR1 ERK signaling pathway, Kanglexin promotes angiogenesis and accelerates wound healing in diabetes. Additionally, it has lipid-lowering effects and inhibits vascular smooth muscle cell dedifferentiation, making it a potential compound for studying hyperlipidemia, fatty liver, and atherosclerosis.

Glembatumumab vedotin (CDX-011) is an antibody-drug conjugate with potent anticancer effects, utilized in the study of triple negative breast cancer (TNBC).

Glenzocimab (ACT017), a Fab fragment of a humanized anti-GPVI monoclonal antibody, demonstrated inhibition of collagen-induced platelet aggregation in an ischemic stroke model and has been studied in acute ischemic stroke and cerebral thrombosis.

Gleditsioside J is a useful organic compound for research related to life sciences. The catalog number is T125199 and the CAS number is 253123-52-3.

Gleditsioside 1 is a useful organic compound for research related to life sciences. The catalog number is T125270 and the CAS number is 229468-56-8.

Ganglefene, an n-cholinergic receptor antagonist, has been shown to induce sexual dysfunction in the adult offspring of pregnant rats administered this compound.

Telaglenastat (CB-839) hydrochloride is a first-in-class, reversible, and orally active inhibitor of glutaminase 1 (GLS1), selectively inhibiting the splice variants KGA (kidney-type glutaminase) and GAC (glutaminase C), as opposed to GLS2. Telaglenastat hydrochloride has an IC50 of 23 nM for endogenous glutaminase in mouse kidney and 28 nM in the brain, inducing autophagy and exhibiting antitumor activity.

Efpeglenatide is a long-acting agonist of the glucagon-like peptide (GLP-1) receptor. efpeglenatide improves insulin sensitivity and slows weight loss in mice models of diabetes and obesity. efpeglenatide has been used in studies of type II diabetes.

Glenvastatin is a HMG-CoA reductase inhibitor which has a pyridine-based structure.

Gletimbetasin is an analog of thymosin (thymosin) β4, possessing anti-inflammatory properties.

Glemanserin (MDL11939) is a specific 5-HT2A antagonist with Ki values of 0.54 nM, 2.5 nM and 2.89 nM for rabbit, human and rat 5-HT2A.

Glembatumumab is a fully human IgG2 monoclonal antibody targeting the extracellular structural domain of GPNMB expressed in human breast cancer and melanoma. It is a naked antibody to Glembatumumab vedotin and can be used to study antibody-activated molecule couplings (Glembatumumab vedotin).

1. Negletein (7-O-Methylbaicalein) has anti-inflammatory and immunomodulatory activities via inhibition of TNF-α, iNOS and IL-1β. 2. Negletein as a neuroprotectant enhances the action of nerve growth factor and induces neurite outgrowth in PC12 cells. 3. Negletein shows a comparable redox-active potential, and it (50 μM, 4 h) can activate Nrf2. 4. Negletein shows significant antimicrobial activity. 5. Negletein has anti-hypoxia activity, it can significantly prolong the survival time of hypoxic mice.6. Negletein has anti- Alzheimer's disease activity, it inhibits the iron-dependent formation of ROS and also blocks the iron-induced oligomerization of amyloid beta 42 in vitro. 7. Negletein (IC50: 3.89 + - 0.39 microM) exhibits potent inhibitory activity against nuclear factor of activated T cells (NFAT) transcription factor.

Gleditsioside F is a useful organic compound for research related to life sciences. The catalog number is T125294 and the CAS number is 225524-86-7.

Eupaglehnin C shows cytotoxic (2.19 mg/ml) against HeLa-S3.